FDA grants Palobiofarma approval to start second anti-cancer study in USA

Palobiofarma has received FDA approval to initiate a Phase I clinical trial with the novel adenosine A2b antagonist PBF-1129 in lung cancer patients. The trial will be conducted at Ohio State University Comprehensive Cancer Center, Ohio, USA.

The release as fetched from its publisher. palobiofarma.com ↗